55197-36-9

Basic information

• Product Name: 3-(4-Aminomethyl-phenyl)-propionic acid
• Synonyms: 3-(4-Aminomethyl-phenyl)-propionic acid;4-(Aminomethyl)benzenepropanoic acid;Benzenepropanoic acid, 4-(aminomethyl)-
• CAS NO: 55197-36-9
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.21572
• EINECS: -0
• Mol File: 55197-36-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 255 °C(Solv: ethanol, 25% (64-17-5))
• Boiling Point: 347.1±22.0 °C(Predicted)
• Appearance: /
• Density: 1.168±0.06 g/cm3(Predicted)
• PKA: 4.55±0.10(Predicted)
• CAS DataBase Reference: 3-(4-Aminomethyl-phenyl)-propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Aminomethyl-phenyl)-propionic acid(55197-36-9)
• EPA Substance Registry System: 3-(4-Aminomethyl-phenyl)-propionic acid(55197-36-9)

Safety Data

• Hazardous Substances Data: 55197-36-9(Hazardous Substances Data)

Usage

General Description

3-(4-aminomethyl-phenyl)-propionic acid, also known as flurbiprofen, is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used to relieve pain, inflammation, and fever. It works by blocking the production of certain natural substances in the body that cause pain and inflammation. Flurbiprofen is typically prescribed for the treatment of rheumatoid arthritis, osteoarthritis, and other musculoskeletal conditions. It is available in various forms including oral tablets, capsules, and a topical solution for topical application. Like other NSAIDs, flurbiprofen may cause side effects such as stomach irritation, ulcers, and bleeding, and should be used with caution in patients with a history of these conditions.

Upstream product

• 16642-94-7 (E)-4-cyanocinnamic acid 
• 501-52-0 3-Phenylpropionic acid 
• 56703-33-4 β-(p-chloromethylphenyl)propionic acid 

Downstream Products

• 919528-86-2 3-(4-{[(fluoren-9-ylmethoxy)carbonylamino]-methyl}phenyl)propanoic acid 
• 1173158-26-3 3-{4-[(prop-2-enyloxycarbonylamino)methyl]phenyl}propanoic acid 
• 1173158-31-0 N-{[4-(3-hydroxypropyl)phenyl]methyl}prop-2-enyloxycarboxamide 
• 1173158-36-5 C₂₂H₂₂N₂O₅ 
• 1173156-17-6 2-{[2-({[N-({4-[3-((2R)-2-amino-4-phenylbutanoylaminooxy)propyl]phenyl}methyl)carbamoyl]methyl}{2-[bis(carboxymethyl)amino]ethyl}amino)ethyl](carboxymethyl)amino}acetic acid trifluoroacetic acid salt 
• 1173158-46-7 C₅₅H₈₈N₆O₁₃ 
• 1173158-44-5 (2R)-N-{3-[4-(aminomethyl)phenyl]propoxy}-2-[(tert-butoxy)carbonylamino]-4-phenylbutanamide trifluoroacetic acid salt 
• 1173158-45-6 C₂₉H₃₉N₃O₆ 
• 1173156-15-4 2-{[2-({[N-({4-[3-((2R)-2-amino-3-indol-3-ylpropanoylaminooxy)propyl]phenyl}methyl)carbamoyl]methyl}{2-[bis(carboxymethyl)amino]ethyl}amino)ethyl](carboxymethyl)amino}acetic acid trifluoroacetic acid salt 
• 1173158-42-3 C₅₆H₈₇N₇O₁₃ 
• 1173158-39-8 (2R)-N-{3-[4-(aminomethyl)phenyl]propoxy}-2-[(tert-butoxy)carbonylamino]-3-indol-3-ylpropanamide trifluoroacetic acid salt 
• 1173158-41-2 C₃₀H₃₈N₄O₆ 
• 1173158-33-2 N-({4-[3-(aminooxy)propyl]phenyl}methyl)prop-2-enyloxycarboxamide hydrochloric acid salt 

Relevant articles and documents

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Synthesis of isosteres of p-amidinophenylpyruvic acid. Inhibitors of trypsin thrombin, and pancreatic kallikrein.

A series of amino acids, amidino acids, and amidino esters was synthesized and the compounds were evaluated for their inhibitory activity against bovine trypsin, bovine thrombin, and porcine pancreatic kallikrein and as anticoagulants. Among these compounds, ethyl 4-amidino-2-iodophenoxyacetate was found to be the most effective inhibitor of the enzymes in question, with a potency (Ki = 3.16 x 10-6 M vs. trypsin; Ki = 4.8 x 10-5 M vs. thrombin) similar to that of p-amidinophenylpyruvic acid (Ki = 6.0 x 10-6 M vs. trypsin; Ki = 2.0 x 10-5 M vs. thrombin). Ethyl 4-amidino-2-iodophenoxyacetate was also found to be the most effective in blocking the clotting activity of plasma, as indicated by significant prolongation of the partial thromboplastin time. This paper reports the synthetic methods, the enzyme inhibitory activity, and the structure-activity relationships observed.